LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

·       LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform

·       LCB Eligible to receive up to $1.25 billion

Daejeon, Dec 23, 2022

LegoChem Biosciences, Inc. (141080KS, ‘LCB’) announced on December xx that it has entered into a research collaboration and license agreement with Amgen, whereby it granted Amgen rights to research, develop, and commercialize ADCs directed against up to 5 targets ed by Amgen based on LCB’s proprietary ConjuAll ADC technology.  

Under the terms of the agreement, LCB is eligible to receive up to $1.25 billion including upfront, development and commercial milestone payments and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.

LCB’s clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-ively activating linker and payload technologies for ADCs. It overcomes the limitations associated with conventional technologies that produce heterogeneous ADCs with its greater potency, safety and stability, and enables the development ADCs with a wider therapeutic window and improved manufacturability.

'Amgen has a proven track record of bringing transformative medicines to market, and we are pleased that they ed our ADC technology to integrate with their efforts to develop next-generation ADCs,” said Yong-Zu Kim, LCB’s President and CEO. “This licensing agreement demonstrates LCB’s continued recognition as an industry-leading ADC player and further enhances our ability to innovate through global partnership as we build out our pipeline and accelerate our transformation into a fully-integrated oncology company.”

LCB has continued to build a robust ADC licensing deal flow with 12 transactions completed with a cumulative deal volume of over $5 billion.